Tandem mass spectrometry as screening for inborn errors of metabolism;Tamiz de los errores innatos del metabolismo por espectrometría de masas en tándem: Principales biomarcadores

Revista Medica de Chile

Volumn 139, Issue 10, 2011, Pages 1356-1364

  Derbis Campos, H ^a,b  

^a Centro Nacional de Genetica Medica   (Cuba)

^b UNIVERSITY OF HAVANA   (Cuba)

Author keywords

Amino acid metabolism; Inborn errors; Phenylketonurias; Spectrum analysis

Indexed keywords

BIOLOGICAL MARKER;

CLASSIFICATION; HUMAN; INBORN ERROR OF METABOLISM; LABORATORY DIAGNOSIS; METHODOLOGY; NEWBORN; NEWBORN SCREENING; REVIEW; TANDEM MASS SPECTROMETRY;

BIOLOGICAL MARKERS; FALSE POSITIVE REACTIONS; HUMANS; INFANT, NEWBORN; METABOLISM, INBORN ERRORS; NEONATAL SCREENING; TANDEM MASS SPECTROMETRY;

EID: 84855521310     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: 10.4067/S0034-98872011001000017     Document Type: Review

References (48)

1. Campos Hernández D. Tamizaje neonatal por espectrometría de masas en tándem: actualización. Rev Panam Salud Publica 2010; 27: 309-18.
2. Lukacs Z, Santer R. Evaluation of electrospray-tandem mass spectrometry for the detection of phenylketonuria and other rare disorders. Mol Nutr Food Res 2006; 50: 443-50.
3. Schulze A, Lindner M, Kohlmüller D, Olgemöller K, Mayatepek E, Hoffmann GF. Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics 2003; 11: 1399-406.
4. Ceglarek U, Müller P, Stach B, Bührdel P, Thiery J, Kiess W. Validation of the phenylalanine/tyrosine ratio determined by tandem mass spectrometry: sensitive newborn screening for phenylketonuria. Clin Chem Lab Med 2002; 40: 693-7.
5. Zytkovicz TH, Fitzgerald EF, Marsden D, Larson CA, Shih VE, Johnson DM, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem 2001; 47: 1945-55.
6. Kasper DC, Ratschmann R, Metz TF, Mechtler TP, Möslinger D, Konstantopoulou V, et al. The national Austrian newborn screening program-eight years experience with mass spectrometry. Past, present, and future goals. Wien Klin Wochenschr 2010; 122: 607-13.
7. Oglesbee D, Sanders KA, Lacey JM, Magera MJ, Casetta B, Strauss KA, et al. Second-tier test for quantification of alloisoleucine and branched-chain amino acids in dried blood spots to improve newborn screening for maple syrup urine disease (MSUD). Clin Chem 2008; 54: 542-9.
8. De Jesús VR, Chace DH, Lim TH, Mei JV, Hannon WH. Comparison of amino acids and acylcarnitines assay methods used in newborn screening assays by tandem mass spectrometry. Clin Chim Acta 2010; 411: 684-9.
9. Schutzman DL, Porat R, Salvador A, Janeczko M. Neonatal nutrition: a brief review. World J Pediatr 2008; 4: 248-53.
10. Puckett RL, Lorey F, Rinaldo P, Lipson MH, Matern D, Sowa ME, et al. Maple syrup urine disease: further evidence that newborn screening may fail to identify variant forms. Mol Genet Metab 2010; 100: 136-42.
11. Oglesbee D, Sanders KA, Lacey JM, Magera MJ, Casetta B, Strauss KA, et al. Second-tier test for quantification of alloisoleucine and branched-chain amino acids in dried blood spots to improve newborn screening for maple syrup urine disease (MSUD). Clin Chem 2008; 54: 542-9.
12. Chace DH, Kalas T, Naylor EW. Use of tandem mass spectrometry for multianalyte screening on dried blood specimens from newborns. Clin Chem 2003; 49: 1797-817.
13. Torres-Sepúlveda MR, Martínez-De Villarreal LE, Esmer C, González-Alanís R, Ruiz-Herrera C, Sánchez-Peña A, et al. Tamiz metabólico neonatal por espectrometría de masas en tándem: dos años de experiencia en Nuevo León, México. Salud Publica Mex 2008; 50: 200-6.
14. Allard P, Grenier A, Korson MS, Zytkovicz TH. Newborn screening for hepatorenal tyrosinaemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots. Clin Biochem 2004; 37: 1010-5.
15. Chace DH, Lim T, Hansen CR, De Jesus VR, Hannon WH. Improved MS/MS analysis of succinylacetone extracted from dried blood spots when combined with amino acids and acylcarnitine butyl esters. Clin Chim Acta 2009; 407: 6-9.
16. Dhillon KS, Bhandal AS, Aznar CP, Lorey FW, Neogi P. Improved tandem mass spectrometry (MS/MS) derivatized method for the detection of tyrosinemia type I, amino acids and acylcarnitine disorders using a single extraction process. Clin Chim Acta. 2011 Jan 7.
17. Matern D, Tortorelli S, Oglesbee D, Gavrilov D, Rinaldo P. Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: the Mayo Clinic experience (2004-2007). J Inherit Metab Dis 2007; 30: 585-92.
18. Rhead WJ. Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: a global perspective. J Inherit Metab Dis 2006; 29: 370-7.
19. Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem 2003; 49: 1797-817.
20. Van Hove JL, Zhang W, Kahler SG, Roe CR, Chen YT, Terada N, et al. Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: diagnosis by acylcarnitine analysis in blood. Am J Hum Genet 1993; 52: 958-66.
21. Okun JG, Kölker S, Schulze A, Kohlmüller D, Olgemöller K, Lindner M, et al. A method for quantitative acylcarnitine profiling in human skin fibroblasts using unlabelled palmitic acid: diagnosis of fatty acid oxidation disorders and differentiation between biochemical phenotypes of MCAD deficiency. Biochim Biophys Acta 2002; 1584: 91-8.
22. Koeberl DD, Young SP, Gregersen NS, Vockley J, Smith WE, Benjamin DK Jr, et al. Rare disorders of metabolism with elevated butyryl-and isobutyryl-carnitine detected by tandem mass spectrometry newborn screening. Pediatr Res 2003; 54: b219-23.
23. Chace DH, Diperna JC, Mitchell BL, Sgroi B, Hofman LF, Naylor EW. Electrospray tandem mass spectrometry for analysis of acylcarnitines in dried postmortem blood specimens collected at autopsy from infants with unexplained cause of death. Clin Chem 2001; 47: 1166-82.
24. Sim KG, Wiley V, Carpenter K, Wilcken B. Carnitine palmitoyltransferase I deficiency in neonate identified by dried blood spot free carnitine and acylcarnitine profile. J Inherit Metab Dis 2001; 24: 51-9.
25. Fingerhut R, Ensenauer R, Röschinger W, Arnecke R, Olgemöller B, Roscher AA. Stability of acylcarnitines and free carnitine in dried blood samples: implications for retrospective diagnosis of inborn errors of metabolism and neonatal screening for carnitine transporter deficiency. Anal Chem 2009; 81: 3571-5.
26. Fingerhut R, Röschinger W, Muntau AC, Dame T, Kreischer J, Arnecke R, et al. Hepatic carnitine palmitoyltransferase I deficiency: acylcarnitine profiles in blood spots are highly specific. Clin Chem 2001; 47: 1763-8.
27. Wilcken B. Disorders of the carnitine cycle and detection by newborn screening. Ann Acad Med Singapore 2008; 37: 71-3.
28. Sigauke E, Rakheja D, Kitson K, Bennett MJ. Carnitine palmitoyltransferase II deficiency: a clinical, biochemical, and molecular review. Lab Invest 2003; 83: 1543-54.
29. Chace DH, Diperna JC, Kalas RA, Johnson RW, Naylor EW. Rapid Diagnosis of Methylmalonic and propionic acidemias: quantitative tandem mass spectrometric analysis of propionylcarnitine in filter-paper blood specimens obtained from newborns. Clin Chem 2001; 47: 2040-4.
30. Fletcher J. Disorders of vitamin B12 metabolism presenting through newborn screening. Ann Acad Med Singapore 2008; 37: 79-2.
31. Nennstiel-Ratzel U, Blankenstein O, Ceglarek U, Starke I, Stoppsack M, Rauterberg E, et al. National Screening Report 2004. [monografía en Internet]. Deutsche Gesellschaft für Neugeborenenscreening (DGNS); 2004. Disponible en: http://www.screening-dgns.de/PDF/Screeningreport_2004_e.pdf [Consultado el 25 de agosto de 2009].
32. Lindner M, Ho S, Kölker S, Abdoh G, Hoffmann GF, Burgard P. Newborn screening for methylmalonic acidurias-optimization by statistical parameter combination. J Inherit Metab Dis 2008; 31: 379-85.
33. Cheng KH, Liu MY, Kao CH, Chen YJ, Hsiao KJ, Liu TT, et al. Newborn screening for methylmalonic aciduria by tandem mass spectrometry: 7 years' experience from two centers in Taiwan. J Chin Med Assoc 2010; 73: 314-8.
34. Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 2003; 348: 2304-12.
35. Baumgartner C, Baumgartner D. Biomarker discovery, disease classification, and similarity query processing on high-throughput MS/MS data of inborn errors of metabolism. J Biomol Screen 2006; 11: 90-9.
36. Chace DH, Kalas TA. A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing. Clin Biochem 2005; 38: 296-309.
37. Wei CC, Lin WD, Tsai FJ, Wu JY, Peng CT, Tsai CH. Isovaleric acidemia diagnosed promptly by tandem mass spectrometry: report of one case. Acta Paediatr Taiwan 2004; 45: 236-8.
38. Van Calcar SC, Gleason LA, Lindh H, Hoffman G, Rhead W, Vockley G, et al. 2-methylbutyryl-CoA dehydrogenase deficiency in Hmong infants identified by expanded newborn screen. WMJ 2007; 106: 12-5.
39. Shigematsu Y, Hata I, Kikawa Y, Mayumi M, Tanaka Y, Sudo M, et al. Modifications in electrospray tandem mass spectrometry for a neonatal-screening pilot study in Japan. J Chromatogr B, Biomed Sci Apl 1999; 731: 97-103.
40. La Marca G, Malvagia S, Pasquini E, Innocenti M, Donati MA, Zammarchi E. Rapid 2nd-tier test for measurement of 3-OH-propionic and methylmalonic acids on dried blood spots: reducing the false-positive rate for propionylcarnitine during expanded newborn screening by liquid chromatography-tandem mass spectrometry. Clin Chem 2007; 53: 1364-9.
41. Shigematsu Y, Hata I, Tanaka Y. Stable-isotope dilution measurement of isovalerylglycine by tandem mass spectrometry in newborn screening for isovaleric academia. Clin Chim Acta 2007; 386: 82-6.
42. Frazier DM. Tyrosine results in MS/MS newborn screening: the highs and lows. Newborn Screening and Genetic Testing Symposium. [monografía en Internet] Minneapolis; 2007. Disponible en: http://www.aphl.org/profdev/conferences/proceedings/Documents/2007_NBS_and_Genetic_Testing_Symposium/Tyrosine_Results_in_NBS.pdf [Consultado el 22 de octubre de 2009].
43. Magera MJ, Gunawardena ND, Hahn SH, Tortorelli S, Mitchell GA, Goodman SI, et al. Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinaemia type I. Mol Genet Metab 2006; 88: 16-21.
44. Matern D, Tortorelli S, Oglesbee D, Gavrilov D, Rinaldo P. Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: the Mayo Clinic experience (2004-2007). J Inherit Metab Dis 2007; 30: 585-92.
45. Fingerhut R, Ensenauer R, Röschinger W, Arnecke R, Olgemöller B, Roscher AA. Stability of acylcarnitines and free carnitine in dried blood samples: implications for retrospective diagnosis of inborn errors of metabolism and neonatal screening for carnitine transporter deficiency. Anal Chem 2009; 81: 3571-5.
46. Cavedon CT, Bourdoux P, Mertens K, Van Thi HV, Herremans N, De Laet C. Age-related variations in acylcarnitine and free carnitine concentrations measured by tandem mass spectrometry. Clin Chem 2005; 51: 745-52.
47. Holub M, Tuschl K, Ratschmann R, Strnadová KA, Mühl A, Heinze G, et al. Influence of hematocrit and localisation of punch in dried blood spots on levels of amino acids and acylcarnitines measured by tandem mass spectrometry. Clin Chim Acta 2006; 373: 27-31.
48. Tran K, Banerjee S, Li H, Noorani HZ, Mensinkai S, Dooley K. Clinical efficacy and cost-effectiveness of newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry. Clin Biochem 2007; 40: 235-41.